Cogstate and Eisai establish
a global partnership to develop
and commercialize digital brain
health assessment tools
LEARN ABOUT THE PARTNERSHIP
At Cogstate, we believe that brain health is profoundly important to quality of life and should be easier to measure. That is why we so passionately apply our expertise, access to data and flexible technology to radically simplify the assessment of cognition and other outcome measures to improve clinical research and clinical care around the world.
Solutions to optimize clinical outcome assessments to better measure drug efficacy and safety
Cogstate Ltd (ASX:CGS) is a leading neuroscience technology company optimizing brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerized cognitive tests across a growing list of domains and support electronic clinical outcome assessment (eCOA) solutions to replace costly and error-prone paper assessments with real-time data capture.
The company’s clinical trials solutions include quality assurance services for study endpoints that combine innovative operational approaches, advanced analytics and scientific consulting. For more than 20 years, Cogstate has proudly supported the leading-edge research needs of biopharmaceutical companies and academic institutions and the clinical care needs of physicians and patients around the world.
How can we help you optimize the measurement of brain health?